Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioAtla, Inc.

0.3438
+0.01966.05%
Post-market: 0.34380.00000.00%18:51 EDT
Volume:488.35K
Turnover:165.98K
Market Cap:19.95M
PE:-0.20
High:0.3499
Open:0.3400
Low:0.3301
Close:0.3242
Loading ...

Company Profile

Company Name:
BioAtla, Inc.
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
65
Office Location:
11085 Torreyana Road,San Diego,California,United States
Zip Code:
92121
Fax:
858 558 0709
Introduction:
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

Directors

Name
Position
Jay M. Short
Chairman and Chief Executive Officer
Scott Smith
President and Director
Guy Levy
Director
Lawrence Steinman
Director
Mary Ann Gray
Director
Priyanka Belawat
Director
Susan Moran
Director

Shareholders

Name
Position
Jay M. Short
Chairman and Chief Executive Officer
Richard A. Waldron
Chief Financial Officer
Carolyn Anderson Short
Chief of Intellectual Property and Strategy and Assistant Secretary
Christian Vasquez
Vice President of Finance, Corporate Controller and Secretary
Eric Sievers
Chief Medical Officer
Scott Smith
President and Director